When Everyone Is an Orphan: Against Adopting a U.S.-Styled Orphan Drug Policy in Canada
نویسندگان
چکیده
منابع مشابه
Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997–2012
We examined whether access to US-approved orphan drugs in Canada has changed between 1997 (when Canada chose not to adopt an orphan drug policy) and 2012 (when Canada reversed its policy decision). Specifically, we looked at two dimensions of access to US-approved orphan drugs in Canada: (1) regulatory access; and (2) temporal access. Whereas only 63% of US-approved orphan drugs were granted re...
متن کاملAdopting an orphan
507 suggests that there must be some pathogens that affect both plants and animals. Indeed, one such example is the bacterium Pseudomonas aeruginosa, which attacks both Homo sapiens and Arabidopsis. Perhaps more significant are the common conditions that arise when the immune system malfunctions. There are many known autoimmune diseases in humans, but plants also suffer from them. In lesion mim...
متن کاملOrphan drug incentives in the pharmacogenomic context: policy responses in the US and Canada
Advances in pharmacogenomic research and increasing industry interest in personalized medicine have important implications for the way that orphan drug policies are interpreted and applied. Concerns have been raised about the potential impact of pharmacogenomics and new genomic technologies on our understanding of how disease categories are delineated, and subsequently, how the concept of rare ...
متن کاملMethadone: An Orphan Drug?
73 Dear Editor: A pharmaceutical product is called “orphan drug” when, although promising or clearly valid from a scientific and therapeutic point of view, it is not profit-bearing and, therefore, not interesting for the pharmaceutical industry. The consequences are the lack of extensive research on its effects, and mainly, the lack of appropriate information to physicians, nurses, and administ...
متن کاملOptimizing an Orphan Drug Framework for Canada Canada’s Orphan Drug Framework: Lessons from the United States, Europe and Japan
Canada is in the process of developing an orphan drug regulatory framework (the “Canadian Framework”) 1 in which an orphan drug is defined as one targeting a disease that affects fewer than 5 in 10,000 Canadians. The federal government announced the development of the Canadian Framework in 2012. Health Canada has held workshops and announced pilot projects related to the Canadian Framework, but...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Accountability in Research
سال: 2013
ISSN: 0898-9621,1545-5815
DOI: 10.1080/08989621.2013.793120